ABSTRACT
Renal cell carcinoma (RCC), a prevalent and aggressive urinary system tumor, has limited treatment success and overall poor patient outcomes. Interestingly, some patients who respond well to treatment exhibit long-term symptom relief and are considered ‘cured.’ Our study’s aim was to uncover essential genes and pathways related to RCC using two methods: WGCNA for gene network analysis and the 3-parameter defective Gompertz model to pinpoint therapeutic genes. Through WGCNA, we identified six key modules linked to various aspects of cancer progression and survival. Hub genes, important players in cellular interactions, were identified using network analysis. Using survival analysis, we detected genes associated with patient survival (SRGs) and genes linked to successful treatment outcomes (CSRGs) in RCC. Among the hub genes found using both survival methods, ten were commonly identified by the defective 3-parameter Gompertz and Cox models. Notably, six genes (NCAPG, TTK, DLGAP5, TOP2A, BUB1B, and BUB1) stood out with strong predictive values. Additionally, the defective Gompertz model highlighted six genes (TTK, KIF20A, DLGAP5, BUB1, AURKB, and CDC45) that significantly impacted the cure rate when their expression was at its highest. This suggests that targeting these genes might hold promise for improving RCC treatment outcomes. The hub genes identified also hold potential for predicting patient prognosis and aiding in diagnosis. Our study provides insights into RCC’s molecular underpinnings and emphasizes the potential of the defective 3-parameter Gompertz model in guiding targeted therapeutic approaches.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Cancer Genome Atlas (TCGA) database (https://portal.gdc.cancer.gov/)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
section on authors updated abstract edited and some parts in manuscript
Data Availability
All data produced are available online at: Cancer Genome Atlas (TCGA) database (https://portal.gdc.cancer.gov/)
